Trials / Active Not Recruiting
Active Not RecruitingNCT05168423
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
Phase 1, Open-label Study Evaluating the Safety and Feasibility of CART-EGFR-IL13Ra2 Cells in Patients With EGFR-Amplified Recurrent Glioblastoma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has recurred following prior radiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CART-EGFR-IL13Ra2 Cells | autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2 |
Timeline
- Start date
- 2023-02-24
- Primary completion
- 2039-12-19
- Completion
- 2039-12-19
- First posted
- 2021-12-23
- Last updated
- 2026-04-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05168423. Inclusion in this directory is not an endorsement.